Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

2008507 citationsJournal Articlebronze Open Access

Authors

Abby B. Siegel

E. Cohen · Columbia University

Allyson J. Ocean · Columbia University

Deborah Lehrer · National Cancer Institute

Alec Goldenberg · National Cancer Institute

Jennifer J. Knox · National Cancer Institute

Helen Chen · National Cancer Institute

Abstract

We observed significant clinical and biologic activity for bevacizumab in nonmetastatic HCC and achieved the primary study end point. Serious bleeding complications occurred in 11% of patients. Further evaluation is warranted in carefully selected patients.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cancer Mechanisms and Therapy Angiogenesis and VEGF in Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 18, pp. 2992-2998

DOI: 10.1200/jco.2007.15.9947

Field-Weighted Citation Impact: 26.76